Skip to main
GRAL

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL is a well-positioned healthcare company with a breakthrough multi-cancer early detection blood test and a positive outlook from the management team, seen through their cautious optimism and positive tone regarding FDA approval and the upcoming ASCO data presentation. The company's recent financial performance also highlights strong growth potential, with a beat on Q1 sales and a 50% year-over-year increase in volume. However, risks to the downside include potential delays or limitations in FDA approval and Medicare reimbursement, as well as any slowdown in the self-pay market.

Bears say

GRAIL is facing challenges in establishing the materiality of its healthcare technology, particularly in terms of ESG performance. Factors such as accuracy and specificity of the blood test, as well as the potential impact on patient outcomes and interventions, are key to the success of the company. However, there may be shifts in what is considered most material in the healthcare industry over time, making it difficult to accurately evaluate GRAIL's overall performance.

GRAIL Inc (GRAL) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 8 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.